Skip to content
Sep 09 2015

Small/Micro Cap Biotechnology: Still Richly Valued

  • Sep 9, 2015

Despite the group’s big losses since May, the results show Small/Micro Cap Biotechs are still richly valued. As market volatility heats up, this group faces additional downside risk.


For full access, please enter your credentials.

About The Author

Jun Zhu / Sr. Research Analyst & Co-Portfolio Manager